Circulating cancer cells can putatively colonize distant organs to form metastases or to reinfiltrate primary tumors themselves through a process termed "tumor self-seeding." Here we exploit this biological attribute to deliver tumor necrosis factor alpha (TNF), a potent antitumor cytokine, directly to primary and metastatic tumors in a mechanism that we have defined as "tumor self-targeting." For this purpose, we genetically engineered mouse mammary adenocarcinoma (TSA), melanoma (B16-F10), and Lewis lung carcinoma cells to produce and release murine TNF. In a series of intervention trials, systemic administration of TNF-expressing tumor cells was associated with reduced growth of both primary tumors and metastatic colonies in immunocompetent mice. We show that these malignant cells home to tumors, locally release TNF, damage neovascular endothelium, and induce massive cancer cell apoptosis. We also demonstrate that such tumor-cell-mediated delivery avoids or minimizes common side effects often associated with TNF-based therapy, such as acute inflammation and weight loss. Our study provides proof of concept that genetically modified circulating tumor cells may serve as targeted vectors to deliver anticancer agents. In a clinical context, this unique paradigm represents a personalized approach to be translated into applications potentially using patient-derived circulating tumor cells as self-targeted vectors for drug delivery. 
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engineered tumor cells | tumor necrosis factor | vascular damaging agent | endothelial cells | apoptosis A hallmark of cancer is the dissemination of tumor cells into the vascular system and colonization of distant organs to form metastatic foci. Recent studies showed that circulating cancer cells can traffic from primary or metastatic lesions to the peripheral blood and then back to their tumor of origin through a process termed "self-seeding" (1, 2) . This process is proposed to mediate cancer progression by recruiting circulating tumor cells capable of surviving under harsh conditions in the bloodstream, thereby promoting both primary tumor growth and secondary metastatic dissemination (1, 3) . Such homing properties may be facilitated by the presence of blood vessels with altered vascular endothelial barrier function in tumors (2, 4) and by the presence of a favorable tumor microenvironment (1) .
This unique concept provides a rationale for exploiting cancer cells (5) as vehicles to deliver therapeutic agents to tumors, referred to hereafter as ("tumor self-targeting"). Indeed, oncolytic viruses incorporated within cancer cells have been shown to target lung metastases, being protected from circulating antibodies (5-7). Thus, we reasoned that "armed" tumor cells genetically manipulated to express anticancer cytokines and subsequently administered into the bloodstream should be able to deliver such factors focally to both primary and metastatic lesions as a therapeutic strategy. This delivery method may circumvent toxicity and activation of systemic counterregulatory mechanisms, which currently cause major limitations for cytokine biotherapy against cancer (8) . To address this hypothesis experimentally, we engineered murine mammary adenocarcinoma, melanoma, and lung carcinoma cells to produce and release tumor necrosis factor alpha (TNF), a cytokine that damages the tumor vascular endothelia and has anticancer activity (9-11). The rationale for choosing this cytokine is based on our previous work that demonstrated ligand-based delivery of extremely low concentrations of TNF to tumor blood vessels markedly inhibits tumor growth in various xenograft (12) (13) (14) experimental mouse tumor models, and in a variety of native tumors in pet dogs (15) . We show that systemic administration of several types of TNF-expressing cancer cells in syngeneic and nonsyngeneic tumor-bearing mice inhibits the growth of primary and metastatic cancers. We provide evidence that this effect is due to specific targeting to tumors, whereby injected cells accumulate and locally release TNF, resulting in tumor vasculature damage and tumor cell apoptosis.
Results TNF-Expressing Tumor Cells: In Vitro and in Vivo Characterization. To exploit the concept of tumor self-targeting for the delivery of TNF to primary and metastatic tumor sites, we transduced murine TSA mammary adenocarcinoma tumor cells, B16-F10 melanoma cells, and Lewis lung cancer (LLC) cells with a lentiviral vector containing the murine TNF gene (pLenti-mtnf). The amount of bioactive TNF released in the supernatants of lentivirus-transduced Significance A recent paradigm shift has established "tumor cell seeding" as an intriguing biological phenomenon in cancer biology. However, the clinical implications of a bidirectional flow of cancer cells remains largely unexplored. We show that systemic administration of TNFexpressing cancer cells reduces growth of both primary tumors and metastatic colonies defined here as "tumor self-targeting." Our findings support a provocative concept in which circulating tumor cells genetically manipulated ex vivo and readministered into the circulating bloodstream may indeed serve as tumor-targeted cellular vectors in preclinical settings and could potentially open a field of translational investigation.
cells was evaluated with a sensitive cell-based cytolytic assay (Fig. 1A) . Through this approach, we generated tumor cell populations that produce levels of TNF that span three to four orders of magnitude, hereafter defined as: TSA (Fig. 1B) . Furthermore, escalating doses of exogenous, recombinant TNF (0.5-500 ng/mL) did not exert cytotoxic effects on parental tumor cells (Fig. 1C ). These results demonstrate that TNF does not affect tumor cell growth and viability in vitro.
Next, the tumorigenic and metastatic potential of TNF-expressing tumor cells was investigated by administering TNF-expressing TSA, B16-F10, or LLC cells to immunocompetent syngeneic mice, either s.c. or i.v. TNF expression levels correlated with reduced growth rates of all s.c.-implanted tumors (Fig. 1D) , as well as with the number of metastatic colonies in the lungs (Fig. 1E) , compared with tumor numbers produced by the parental tumor cells. Of note, TNFexpressing TSA tumor cells did not grow at all, presumably as a consequence of the highest levels of secreted TNF (Fig. 1A) . Furthermore, these mice were protected from subsequent s.c. challenges with parental TSA cells (Fig. 1F) . Taken together, these results demonstrate that TNF secreted by tumor cells has an antitumor effect on both primary and metastatic tumors in vivo.
TNF-Expressing Cancer Cells Inhibit the Growth of Primary Tumors
and Lung Colonies in Mice. To evaluate the potential therapeutic application of TNF-expressing tumor cells, we investigated the tnf or TSA tnf i.v. injection in C57BL/6 mice (syngeneic for B16-F10 cells, nonsyngeneic for TSA cells). Lungs were inspected for the presence of visual colonies at day 26 (n = 4, mean ± SEM). *P < 0.05; **P < 0.01; ***P < 0.001 by Student's t test, two tailed.
flank was unable to inhibit growth of the established s.c.-implanted TSA tumor (Fig. S1A) ; in contrast, when TSA tnf cells were i.v. administered, tumor growth of the established s.c.-implanted TSA tumor was inhibited (Fig. S1B ). This intriguing observation indicates that the presence of TNF-expressing tumor cells in the vascular circulation is critical for antitumor activity of the primary tumor.
To determine whether i.v.-administered TNF-expressing cells would limit the growth of metastatic tumors, mice were injected i.v. with TSA, B16-F10, or LLC parental tumor cells and allowed to circulate and form lung colonies. One week later, tumor-bearing mice were injected i.v. with TSA tnf , B16-F10 tnf , or LLC tnf tumor cells, respectively. Tumor-bearing mice were killed to quantify the number of metastatic lung colonies at 14 (TSA), 11 (B16-F10), or 28 (LLC) days, postinjection of each of the three tumor types. Remarkably, the number of metastatic colonies in the lungs of mice treated with TNF-expressing tumor cells was significantly reduced compared with control mice (Fig. 2B) . Taken together, these data demonstrate that systemic administration of TNF-expressing cancer cells partially inhibits the growth of tumors in the primary and metastatic settings. (Fig. 2C, Left graph) .
day), we found no significant difference in their antitumor activity (Fig. 2C, Right graph) . These independent results are in line with the data shown in Fig. 2A and indicate that the antitumor effect of TNF-expressing cells does not require a large concentration of TNF to inhibit tumor growth. Rather, tumor growth inhibition is proportional to the number of TNF-expressing tumor cells administered.
Irradiated TSA tnf Cells Partially Inhibit Tumor Growth. To assess whether TSA tnf cells retained any antitumor activity in the absence of proliferation, we irradiated them to induce cell cycle arrest (16) . Irradiation reduced the cell proliferation index without affecting TNF production (Fig. S2A) . When these cells were injected into mice bearing s.c. TSA tumors, they showed a nonsignificant tumor volume reduction, indicating the importance of cell proliferation to support their therapeutic effect (Fig. S2B) .
Systemic Administration of TSA tnf Inhibits the Growth of B16-F10
Tumors. Given that cross-seeding between heterotypic tumors (melanoma and mammary tumors) is experimentally established (1), we next investigated whether the therapeutic effect of TSA tnf cells would be effective in a nonsyngeneic setting using B16-F10 tumors. TSA tnf cells (derived from BALB/c mice) were administered i.v. into C57BL/6 mice bearing s.c.-implanted B16-F10 tumors. We observed antitumor effects similar to those obtained with the syngeneic models described above (Fig. 2D) . As predicted, because TSA tnf cells were administered into nonsyngeneic mice, they were eventually rejected by the host and did not establish lung colonies (Fig. 2E) (Fig. 3A) . The growth rate of TSA tumors was significantly lower in TSA tnf -treated mice (Fig. 3 B and C) ; a result consistent with our hypothesis. It is noteworthy that injected TSA tnf cells did not cause weight loss in TSA tumor-bearing animals (Fig. 3D) , which is a typical toxic side effect caused by conventional therapeutic doses of TNF (13) . The presence of TSA tnf cells was analyzed both in the peripheral blood (at days 1, 2, and 4 after systemic administration) and in tumors (at day 4) by semiquantitative PCR with primers to amplify a sequence in pLenti-mtnf-transduced cells that is absent in the normal mouse genome. We also analyzed the circulating levels and intratumor concentrations of TNF by ELISA (DuoSet, R&D Systems). Notably, pLenti-mtnf DNA was detected in the circulation at day 1 after TSA tnf administration, but not at days 2 or 4 (Fig. 3E, Left) , data indicating that TSA tnf cells are cleared from the systemic circulation. In contrast, PCR analysis revealed an accumulation of pLenti-mtnf DNA in TSA tumors excised at day 4, confirming that TSA tnf cells home to the tumor, thus corroborating the tumor self-seeding hypothesis (Fig.  3E, Right) (2) . TNF was not detected in the circulation by ELISA even when TSA tnf cells were present (Fig. 3F, Left) . By contrast, increased levels of TNF were detected at day 4 in tumors of mice injected with TSA tnf cells compared with mice injected with TSA cells (Fig. 3F, Right) . These experimental findings support our interpretation that TSA tnf cells are capable of homing to tumors and locally releasing TNF. Furthermore, the absence of detectable TNF in the peripheral blood and the lack of weight loss in mice treated with TSA tnf cells strongly indicate that the therapeutic effect is mediated by local cellular production of TNF and not by systemic release from circulating TSA tnf cells. (Fig. 4A) , revealing the presence of vascular endothelial cell damage. To assess whether this vascular damage could cause secondary apoptotic responses in tumors, we analyzed cCasp3 expression 2 d after TSA tnf administration. TSA tnf -treated tumors had larger apoptotic areas compared with TSAtreated tumors (Fig. 4B) , consistent with our experimental hypothesis that tumor growth inhibition is dependent on number of TNFexpressing cells rather than on the amount of TNF expressed per cell. These results indicate that, after homing to tumors, TSA tnf cells release TNF, which in turn, causes local vascular damage, leading to tumor cell apoptosis. , and Gr1 − CD11b + ), we found no significant differences between controls or mice treated with TSA tnf , except for a modest increase of CD4 + T cells (Fig. S3) . These results confirm that the release of TNF by tumor cells does not change the composition of infiltrating inflammatory cells into s.c.-implanted TSA tumors under our experimental conditions.
Discussion
The present study shows that systemic administration of genetically engineered tumor cells that produce and release TNF-a very potent pleiotropic cytokine (10, 11)-inhibits the growth of primary and metastatic tumors in three different murine models: TSA, melanoma (B16-F10), and LLC. These TNF-expressing cells home to tumors, locally release TNF, induce vascular endothelial cell damage, and subsequently cause tumor cell apoptosis, a biological phenomenon defined here as "tumor self-targeting." Our preclinical findings support a provocative paradigm in which tumor cells manipulated ex vivo and administered into the peripheral bloodstream may serve as carriers for the therapeutic delivery of bioactive cytokines and potentially additional proteins, as tumortargeted agents.
The efficacy of cytokines in cancer therapy is often reduced by their toxicity and counterregulatory mechanisms. Such limitations may be partially overcome in the case of TNF and IFNγ by a liganddirected strategy based on cytokine fusion with peptides or antibodies selective for unique surface receptors on tumor endothelial or epithelial cells (12) (13) (14) (15) 17) . However, administration of targeted TNF or IFNγ close to the maximum tolerated dose still leads to systemic activation of counterregulatory mechanisms that reduce their potential anticancer activity (12) . The approach described here represents an alternative and/or additional strategy to deliver cytokines to tumors, which is based on living cells and offers several advantages. First, tumor cells can be engineered to produce and release multiple cytokines into the tumor microenvironment, thus favoring local synergistic interactions that can be achieved with much lower levels of each cytokine. For example, a coexpression of EMAP-II or IFNγ, two cytokines known to enhance TNF activity, may potentially increase the antitumor efficacy of TNF (18, 19) . Second, the presence and amounts of such cytokines can be tailored by using inducible systems to optimize spatiotemporal expression, and further limit cytokine-dependent systemic counterregulatory and toxic effects.
Our characterization of the system demonstrates that the anticancer activity of TNF-expressing cells in vivo is dependent on the number of cells administered, rather than on the amount of TNF released per cell (Fig. 2 A and C) . In fact, we show here that TSA, B16-F10, or LLC cells expressing widely different levels of TNF (from 0.015 to 153 fg per cell per day) induced comparable delays in tumor growth rates. We hypothesize that single cells, even low TNF-producing cells can locally release an amount of TNF that is sufficient to cause endothelial damage in tumor blood vessels. Increasing the numbers of administered cells, regardless of the absolute amounts of secreted TNF per cell, are expected to be paralleled by increased numbers of affected vascular loci, and damage of even a single endothelial cell can theoretically lead to impaired perfusion of an entire capillary that may exponentially affect large tumor areas. In support of our hypothesis, we observed apoptosis of endothelial cells in s.c. tumors as early as 1 d after i.v. injection of TNF-expressing cells that was sequentially followed by marked apoptosis of tumor cells after 2 d. This putative mechanism is further confirmed by the finding that TNF-expressing cells inhibit the growth of preexisting tumors when injected i.v., but not when injected s.c. in the contralateral flank. This suggests the antitumor activity of TNF-expressing cells presumably requires homing to the tumor from the circulation, a key event to induce vascular endothelial damage leading to tumor cell death.
Cancer cells engineered to express antitumor agents reduced both primary tumor and metastatic colony growth, but did not abrogate them. Efficacy of our system, however, could be improved by combination therapy. For example, a significant increase of the response to targeted TNF was found with either chemotherapy or immunotherapy, both active and adoptive (20) (21) (22) . Remarkably, strong synergistic effects were achieved (including tumor eradication), compared with the modest reduction induced by targeted TNF alone (23) . Combinatorial therapy could also improve the treatment of larger cancer lesions due to their density in vascularization. Furthermore, metastatic derivatives showed a superior ability to infiltrate parental tumors (1); therefore, engineering highly metastatic cells may further improve their homing properties and thus efficacy.
Considering the multiple functions of TNF (11) , other mechanisms might perhaps contribute to the antitumor effects of TNFexpressing cells, such as direct cytotoxic effects or activation of inflammatory and immune responses. However, we did not observe any detectable effect on the growth and vitality of tumor cells by tumor-cell-released TNF in vitro. Furthermore, analysis of immune cell infiltrates revealed only a modest and not statistically significant increase in CD4 + T cells upon treatment of s.c. TSA tumors with TNF-expressing cells. These data confirm that cell toxicity and inflammation are not likely to be crucial in TNFmediated inhibition of tumor growth in our experimental models. Interestingly, mice injected s.c. with syngeneic TNF-expressing cells were unable to develop tumors after subsequent challenges with corresponding parental tumor cells. Although further experiments will be needed to clarify this observation, one may speculate that TNF expression causes increased immunogenicity and consequent rejection of cancer cells. Concomitantly or alternatively, TNFexpressing cells may have induced a long-lasting effect at the regional injection site, which negatively impacted VEGF secretion and angiogenesis to create a microenvironment that is no longer permissible for tumor growth.
Finally, although cancer cells may represent a uniquely effective delivery system for cytokines, important safety concerns must be addressed before embarking on translational applications of this work. An obvious concern is the risk that injected tumor cells could give rise to new neoplastic lesions. Our characterization of the tumorigenic and metastatic properties of TNF-expressing tumor cells showed that injection of these cells into the circulation of syngeneic mice, results in lung colonies, even though their tumorigenic and metastatic potential is markedly reduced compared with parental cells. Furthermore, we report that systemic administration of TNF-expressing cells to nonsyngeneic mice inhibited tumor growth to about the same extent as the administration in syngeneic mice, but in the complete absence of lung colonies, representing a further improvement toward addressing the safety concerns. In this case, an immune response likely caused the rejection of the nonsyngeneic cells within a few days, after a period that was sufficient to exert their therapeutic effect. To increase the safety of this approach, and to circumvent any possible escape from the immune system, cytokine-expressing tumor cells could be further engineered to express immunogenic proteins and/or inducible suicide genes (24, 25) with the aim of clearing the injected tumor cells after the desired therapeutic effect is achieved. The observation that the antitumor effects of TNF-releasing cells are similar in nonsyngeneic and syngeneic systems, at least in mice, suggests that a common tumor cell line might be effective in different individuals. This may allow the production of highly standardized and finely controlled cells under good manufacturing conditions and with precise protocols for future translational applications. Extensive studies, however, will be required to demonstrate that the safety issues of this delivery system can be managed in a clinical context.
Materials and Methods
Animal Models. Animal studies were approved by the Institutional Animal Care and Use Committee of The University of Texas, MD Anderson Cancer Center and are described further in SI Materials and Methods.
Cell Lines, Recombinant TNF, and Antibodies. Murine TSA mammary adenocarcinoma cells (derived from BALB/c mice) were provided by Giulia Casorati (San Raffaele Institute, Milan). The following cell lines were purchased from the American Type Culture Collection: murine B16-F10 melanoma, murine Lewis lung carcinoma (both on a C57BL/6 strain), and human EAhy.926 endothelial cells. Murine TNF was prepared by recombinant DNA technology and purified from Escherichia coli cell extracts as described (12) . Rabbit polyclonal anti-cCasp3 and CD31 antibodies were purchased from Cell Signaling Technology.
Preparation of TNF-Expressing Tumor Cells. The coding region for murine TNF in the pET-11b-tnf plasmid (12) was PCR amplified and inserted into the pLenti6/ V5 DEST Gateway Vector (Invitrogen) with the In-fusion cloning kit (Clontech). The resultant pLenti-mtnf vector was transfected into HEK-293FT cells (Invitrogen) by incubation with Lipofectamine 2000 (Invitrogen). Culture medium was replaced after overnight incubation at 37°C in 5% CO 2 , and viral particles were collected 24 and 48 h later and pooled. Supernatants were tested for viral particle content by using Lenti-X GoStix (Clontech). TSA, B16-F10, or LLC cells were transduced with 1-2 mL of virus-containing supernatant. Tumor cells expressing low levels of TNF were selected in the presence of 3 μg/mL blasticidin (Sigma-Aldrich). Derived cell lines were named TSA 
